Lung carcinoma cell inhibitor and preparation method of lung carcinoma cell inhibitor

Abstract

The invention discloses a lung carcinoma cell inhibitor and a preparation method of the lung carcinoma cell inhibitor. According to the preparation method, Ni(NO3)2.6H2O, 2,6-bisbenzimidazole pyridine; and 5-hydroxyisophthalic acid are weighed according to a mol ratio being (0.5-1):1:1; then, water is added and solution is put into a container, the PH value of the solution is regulated to 8.0 to 9.0 by triethylamine, and the solution is uniformly stirred; next, the stirred raw material liquid is put into a reaction kettle, a cover is sealed, the temperature is raised to 110 to 130 DEG C, and then, the heat insulation reaction is carried out for 70 to 90 hours; and a gradient temperature reduction method is adopted for lowering the raw material liquid to the room temperature, and green acicular crystal complexes are obtained, i.e., the lung carcinoma cell inhibitor is obtained. The lung carcinoma cell inhibitor disclosed by the invention has the characteristics of good stability and high inhibition capability, and guide is provided for the lung cancer resistance medicine development.

Description

technical field [0001] The invention belongs to anticancer drugs, in particular to a lung cancer cell inhibitor and a preparation method. Background technique [0002] In 2000, there were more than 10 million new cancers in the world, 6.2 million deaths, and more than 22 million current patients. It is estimated that by 2020, there will be more than 15 million new cancers each year, 10 million deaths, and more than 30 million current patients. Cancer is becoming the number one killer of human beings in the new century. In order to save lives and protect human health, the research and development of new anticancer drugs has become one of the important topics of major new drug creation. [0003] Lung cancer is the most common primary malignant tumor of the lung. The vast majority of lung cancers originate from the bronchial mucosal epithelium, so it is also called bronchial lung cancer. Over the past 50 years, the morbidity and mortality of lung cancer have risen rapidly in c...

AI Technical Summary

Problems solved by technology

[0006] Existing drugs often have many shortcomings: A. Traditional chemotherapy drugs: Although chemotherapy can kill cancer cells, it is also eroding the normal cells and internal organs of the human body, and the side effects are quite serious; at the same time, it is often ineffective for patients with metastatic lung cancer At present, the 5-year survival rate of lung cancer in the world is only 15%, and the toxic and side effects of chemotherapy drugs and tumor metastasis are the main causes of death

However, at present, the target in this field is too single, and there are too few types of drugs that can be applied (for example, Gefitinib and erlotinib are epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) drugs, mainly targeting EFGR gene mutations), so Many patients with advanced lung cancer cannot find suitable drugs for treatment

Images